[go: up one dir, main page]

WO2003000191A3 - Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints - Google Patents

Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints Download PDF

Info

Publication number
WO2003000191A3
WO2003000191A3 PCT/US2002/019718 US0219718W WO03000191A3 WO 2003000191 A3 WO2003000191 A3 WO 2003000191A3 US 0219718 W US0219718 W US 0219718W WO 03000191 A3 WO03000191 A3 WO 03000191A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
composition
hyaluronidase inhibitor
preferred
hyaluronidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019718
Other languages
French (fr)
Other versions
WO2003000191A2 (en
Inventor
Jonathan Thompson
Anna Gosiewska
Susan Niemiec
Sridevi Dhanaraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DePuy International Ltd
Original Assignee
DePuy International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DePuy International Ltd filed Critical DePuy International Ltd
Priority to JP2003506637A priority Critical patent/JP2005521629A/en
Priority to EP02739947A priority patent/EP1423081A4/en
Priority to CA002451248A priority patent/CA2451248A1/en
Publication of WO2003000191A2 publication Critical patent/WO2003000191A2/en
Anticipated expiration legal-status Critical
Publication of WO2003000191A3 publication Critical patent/WO2003000191A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A preferred embodiment of the present invention is directed to a composition and method for treating arthritis comprising one or more glycosaminoglycans in combination with one or more hyaluronidase inhibitor. In a more preferred embodiment the present invention is directed to a composition and method for treating arthritis comprising one or more glycosaminoglycans which would include at least hyaluronic acid in combination with one or more hyaluronidase inhibitors selected from the group consisting of heparan sulphate, dextran sulphate and xylose sulphate. In still a more preferred embodiment the present invention relates to a composition and method for treating arthritis comprising hyaluronic acid co-encapsulated with a hyaluronidase inhibitor in liposomes. Hyaluronic acid in the composition would confer the viscosupplement properties to the joint. The function of the hyaluronidase inhibitor would be to act as a preservative, and protect the hyaluronic acid from premature degradation in the joint. The liposomal encapsulation and delivery of the composition would serve as a slow release depot for the hyaluronic acid and the hyaluronidase inhibitor. This invention therefore provides a means of delivering stable and long lasting high molecular weight HA to the joint. The therpeutic effectiveness of the liposome co-encapsulated hyaluronic acid with the hyaluronidase inhibitor would be greater than simple injection of hyaluronic acid. The preferred method of treatment would be by intra-articular injection of an admixture of hyaluronic acid and a hyaluronidase inhibitor, optionally encapsulated in liposomes. The treatment is more effective than currently available treatments based on HA alone.
PCT/US2002/019718 2001-06-25 2002-06-20 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints Ceased WO2003000191A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003506637A JP2005521629A (en) 2001-06-25 2002-06-20 Composition comprising glycosaminoglycan and hyaluronidase inhibitor for treating arthritic joints
EP02739947A EP1423081A4 (en) 2001-06-25 2002-06-20 COMPOSITION COMPRISING GLYCOSAMINOGLYCANS AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC ARTICULATIONS
CA002451248A CA2451248A1 (en) 2001-06-25 2002-06-20 Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30073401P 2001-06-25 2001-06-25
US60/300,734 2001-06-25
US74102A 2002-06-06 2002-06-06
USDEP-741 2002-06-06

Publications (2)

Publication Number Publication Date
WO2003000191A2 WO2003000191A2 (en) 2003-01-03
WO2003000191A3 true WO2003000191A3 (en) 2004-03-11

Family

ID=26668090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019718 Ceased WO2003000191A2 (en) 2001-06-25 2002-06-20 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints

Country Status (4)

Country Link
EP (1) EP1423081A4 (en)
JP (1) JP2005521629A (en)
CA (1) CA2451248A1 (en)
WO (1) WO2003000191A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109758607A (en) * 2019-03-08 2019-05-17 宁夏妙朗生物科技有限公司 Cross-linked hyaluronic acid gel resistant to hyaluronidase hydrolysis

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4703948B2 (en) * 2003-05-20 2011-06-15 丸善製薬株式会社 Anti-allergic agent, anti-aging agent and anti-aging skin external preparation
CA2577022A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
AU2013270451B2 (en) * 2005-10-03 2016-05-12 Mark A. Pinsky Compositions and methods for improved skin care
AU2006299421B2 (en) 2005-10-03 2013-01-31 Mark A. Pinsky Compositions and methods for improved skin care
EP2543340A1 (en) * 2006-05-19 2013-01-09 Trustees Of Boston University Novel hydrophilic polymers as medical lubricants and gels
US20100323985A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US20110263521A1 (en) * 2007-05-11 2011-10-27 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
ITMI20072348A1 (en) 2007-12-17 2009-06-18 Medichem Srl METHOD FOR CELL RIGENERATION OF HYALURONIC ACID AND ITS COSMETIC COMPOSITION
MX2010012326A (en) * 2008-05-19 2010-12-01 Univ North Carolina Methods and compositions comprising novel cationic lipids.
ITMI20090779A1 (en) * 2009-05-08 2010-11-08 Vitrupharm Srl NUTRITIONAL COMPOSITIONS BASED ON CISTEIN RESVERATROL OR ITS DERIVATIVES OR METABOLITES AND ASTAXANTIN
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
BR112012011336A2 (en) 2009-10-22 2018-10-16 Api Genesis Llc COMPOSITIONS UNDERSTANDING FLAVONOIDS, ITS PREPARATION METHOD, ADHESIVE FOR FLAVONOID APPLICATION, HYDRATED FLAVONOID PRODUCTION METHODS, TOPIC FORMULATION PREPARATION METHODS, AND USE OF FLAVONOID
WO2011160146A1 (en) * 2010-06-23 2011-12-29 Croma-Pharma Gesellschaft M.B.H. Pharmaceutical preparation containing dextran and sodium hyaluronate for the treatment of joint disorders
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
ITRM20100614A1 (en) * 2010-11-24 2012-05-25 D M G Italia S R L PHARMACEUTICAL PREPARATIONS OF ACID 18 GLYCYRRHETIC BETA AND / OR OF ITS DERIVATIVES FOR INTRARTICULAR INFILTRATIONS FOR THE TREATMENT OF INFLAMMATORY ARTROPATHIES
FR2991876B1 (en) * 2012-06-13 2014-11-21 Vivacy Lab COMPOSITION, IN AQUEOUS MEDIUM, COMPRISING AT LEAST ONE HYALURONIC ACID AND AT LEAST ONE WATER-SOLUBLE SALT OF SUCROSE OCTASULFATE
EP3334451B1 (en) * 2015-08-13 2020-10-28 Stoffel, Bertrand Composition for the treatment of joint conditions
DE102016208567A1 (en) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymer solution for viscous supplementation
KR102607729B1 (en) 2017-08-22 2023-11-29 뫼비우스 메디칼 리미티드 Liposomal formulation for joint lubrication
WO2024154134A1 (en) 2023-01-19 2024-07-25 Moebius Medical Ltd. A long-acting liposomal composition for treatment of pain in articular disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239754A (en) * 1976-10-23 1980-12-16 Choay, S.A. Liposomes containing heparin and a process for obtaining them
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6232315B1 (en) * 1998-09-28 2001-05-15 Merck & Co., Inc. Method for treating inflammatory diseases by administering a thrombin inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK191889D0 (en) * 1989-04-20 1989-04-20 Bukh Meditec COSMETIC AGENT
AU5089400A (en) * 1999-06-07 2000-12-28 University Of Sheffield, The Arthritis treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239754A (en) * 1976-10-23 1980-12-16 Choay, S.A. Liposomes containing heparin and a process for obtaining them
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
US6232315B1 (en) * 1998-09-28 2001-05-15 Merck & Co., Inc. Method for treating inflammatory diseases by administering a thrombin inhibitor
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109758607A (en) * 2019-03-08 2019-05-17 宁夏妙朗生物科技有限公司 Cross-linked hyaluronic acid gel resistant to hyaluronidase hydrolysis
CN109758607B (en) * 2019-03-08 2021-07-27 宁夏妙朗生物科技有限公司 Cross-linked hyaluronic acid gel resistant to hyaluronidase hydrolysis

Also Published As

Publication number Publication date
CA2451248A1 (en) 2003-01-03
JP2005521629A (en) 2005-07-21
EP1423081A4 (en) 2005-05-25
EP1423081A2 (en) 2004-06-02
WO2003000191A2 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
WO2003000191A3 (en) Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints
CA2390824A1 (en) Stabilized aqueous acidic antiperspirant compositions and related methods
WO2003063799A3 (en) Compositions and methods for systemic inhibition of cartilage degradation
WO2000032196A3 (en) Inhibitors of multidrug transporters
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
CA2289505A1 (en) Composition for treating hair
WO1999062462A3 (en) Hair treatment compositions
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
BR0311939A (en) pharmaceutical composition, method for treating inflammation in a mammal and use of a protective tissue cytokine
DE69842021D1 (en) Amino-sugar, chondroitin and S-adenosylmethionine-containing compositions
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
CA2371372A1 (en) Copper/amine oxide wood preservatives
WO2001052833A8 (en) Compositions for delivery of a cortisol antagonist
WO2005030753A3 (en) Therapeutic agents useful for treating pain
EE04953B1 (en) Use of zinc aluronate and process for the preparation of a pharmaceutical composition
AR018357A1 (en) PETROSELINIC ACID IN A COMPOSITION AND IN A METHOD TO REDUCE OR ELIMINATE THE IRRITATION OR THE PICAZON OF THE SKIN INDUCED BY ALFA-HYDROXIACIDES
GB2329585A (en) A barrier cream comprising hexamethylenetetramine or derivative thereo
WO2001082938A3 (en) Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate
WO2001091774A3 (en) Method of treating chronic ulcers
WO2006118980A3 (en) Long-chain quaternary ammonium compounds as wood treatment agents
WO2025019344A3 (en) Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2003032925A3 (en) Glycosulfopeptide inhibitors and methods of use thereof
CA2529441A1 (en) Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003506637

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2451248

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002312564

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002739947

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002739947

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002739947

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)